116 related articles for article (PubMed ID: 11888083)
1. Can technology expedite the cervical cancer screening process? A Hong Kong experience using the AutoPap primary screening system with location-guided screening capability.
Chang AR; Lin WF; Chang A; Chong KS
Am J Clin Pathol; 2002 Mar; 117(3):437-43. PubMed ID: 11888083
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity studies of AutoPap System Location-Guided Screening of cervical-vaginal cytologic smears.
Huang TW; Lin TS; Lee JS
Acta Cytol; 1999; 43(3):363-8. PubMed ID: 10349363
[TBL] [Abstract][Full Text] [Related]
3. A feasibility study of the AutoPap system location-guided screening.
Lee JS; Kuan L; Oh S; Patten FW; Wilbur DC
Acta Cytol; 1998; 42(1):221-6. PubMed ID: 9479344
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of the use of the AutoPap screening system as a primary screening and location-guided rescreening device.
Confortini M; Bonardi L; Bulgaresi P; Cariaggi MP; Cecchini S; Ciatto S; Cipparrone I; Galanti L; Maddau C; Matucci M; Rubeca T; Troni GM; Turco P; Zappa M; Carozzi F
Cancer; 2003 Jun; 99(3):129-34. PubMed ID: 12811852
[TBL] [Abstract][Full Text] [Related]
5. The AutoPap system for primary screening in cervical cytology. Comparing the results of a prospective, intended-use study with routine manual practice.
Wilbur DC; Prey MU; Miller WM; Pawlick GF; Colgan TJ
Acta Cytol; 1998; 42(1):214-20. PubMed ID: 9479343
[TBL] [Abstract][Full Text] [Related]
6. [Results of pap smears and immunocytochemical detection of the p16 and Ki67 proteins in women with cervical intraepithelial neoplasia and cervical cancer].
Rokita W; Skawiński D; Zmelonek-Znamirowska A; Kedzia W; Karowicz-Bilińska A; Spaczyński R; Spaczyński M
Ginekol Pol; 2012 Nov; 83(11):822-6. PubMed ID: 23379189
[TBL] [Abstract][Full Text] [Related]
7. Improved quality-control detection of false-negative Pap smears using the Autopap 300 QC system.
Marshall CJ; Rowe L; Bentz JS
Diagn Cytopathol; 1999 Mar; 20(3):170-4. PubMed ID: 10086244
[TBL] [Abstract][Full Text] [Related]
8. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: II. Prospective and archival sensitivity studies.
Patten SF; Lee JS; Wilbur DC; Bonfiglio TA; Colgan TJ; Richart RM; Cramer H; Moinuddin S
Cancer; 1997 Dec; 81(6):343-7. PubMed ID: 9438459
[TBL] [Abstract][Full Text] [Related]
9. Endometrial cells and the AutoPap System for primary screening of cervicovaginal Pap smears.
Walts AE; Thomas P
Diagn Cytopathol; 2002 Oct; 27(4):232-7. PubMed ID: 12357502
[TBL] [Abstract][Full Text] [Related]
10. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia.
Liao SY; Stanbridge EJ
Cancer; 2000 Mar; 88(5):1108-21. PubMed ID: 10699902
[TBL] [Abstract][Full Text] [Related]
11. Loss to follow-up of cervical smears without endocervical columnar cells is not disturbing.
Tacken MA; Braspenning JC; Mulder J; Hermens RP; Nelen WL; de Bakker DH; Grol RP
Eur J Gynaecol Oncol; 2006; 27(1):42-6. PubMed ID: 16550967
[TBL] [Abstract][Full Text] [Related]
12. [The Pap test in HIV-positive women].
Carlucci M; Cimmino A; Fiore MG; Lepera A; Tantimonaco L; Ricco R
Pathologica; 2001 Dec; 93(6):651-3. PubMed ID: 11785116
[TBL] [Abstract][Full Text] [Related]
13. Performance of the AutoPap Primary Screening System in the detection of high-risk cases in cervicovaginal smears.
Alasio LM; Alphandery C; Grassi P; Ruggeri M; De Palo G; Pilotti S
Acta Cytol; 2001; 45(5):704-8. PubMed ID: 11575647
[TBL] [Abstract][Full Text] [Related]
14. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix.
Nieh S; Chen SF; Chu TY; Lai HC; Fu E
Gynecol Oncol; 2003 Oct; 91(1):201-8. PubMed ID: 14529682
[TBL] [Abstract][Full Text] [Related]
15. Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: Challenges in detecting dysplasia.
Adkins BD; Barlow AB; Jack A; Schultenover SJ; Desouki MM; Coogan AC; Weiss VL
Cytopathology; 2018 Jun; 29(3):281-287. PubMed ID: 29488269
[TBL] [Abstract][Full Text] [Related]
16. Association of Abnormal Pap Smear with Occult Cervical Stromal Invasion in Patients with Endometrial Cancer.
Khumthong K; Aue-Aungkul A; Kleebkaow P; Chumworathayi B; Temtanakitpaisan A; Nhokaew W
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2847-2850. PubMed ID: 31554386
[TBL] [Abstract][Full Text] [Related]
17. Is the human papillomavirus test in combination with the Papanicolaou test useful for management of patients with diagnoses of atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions?
Lee NW; Kim D; Park JT; Kim A
Arch Pathol Lab Med; 2001 Nov; 125(11):1453-7. PubMed ID: 11698001
[TBL] [Abstract][Full Text] [Related]
18. Correlation of manual screening and automated (AutoPap 300) analysis of conventional cervicovaginal smears with HPV typing using Digene HC II assay.
Walts AE; Thomas P
Diagn Cytopathol; 2003 Nov; 29(5):256-61. PubMed ID: 14595791
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study.
Fremont-Smith M; Marino J; Griffin B; Spencer L; Bolick D
Cancer; 2004 Oct; 102(5):269-79. PubMed ID: 15386329
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
Bansal M; Zhao C
J Low Genit Tract Dis; 2011 Apr; 15(2):105-9. PubMed ID: 21317806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
